ENDO 2025: GLP-1 Receptor Agonists as Multisystem Therapies in Type 2 Diabetes Management

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

administrator

Related Articles